{Reference Type}: Journal Article
{Title}: The effect of celecoxib for treatment of preterm labor on fetuses during the second trimester of pregnancy: A pilot case series.
{Author}: Ohtsuki M;Chigusa Y;Mogami H;Ueda A;Kawasaki K;Yamaguchi K;Mandai M;Kondoh E;Ohtsuki M;Chigusa Y;Mogami H;Ueda A;Kawasaki K;Yamaguchi K;Mandai M;Kondoh E;
{Journal}: Taiwan J Obstet Gynecol
{Volume}: 61
{Issue}: 2
{Year}: Mar 2022
{Factor}: 1.944
{DOI}: 10.1016/j.tjog.2022.02.015
{Abstract}: <B>OBJECTIVE: </B>Although cyclooxygenase inhibitors effectively suppress uterine contraction, constriction of the fetal ductus arteriosus (DA) and oligohydramnios are major concerns. Celecoxib, a selective cyclooxygenase 2 inhibitor, is a potential potent tocolytic agent, but there are no studies that have evaluated the beneficial or adverse effects of celecoxib use on fetuses for more than 48 hours in pregnant women. We therefore aimed to evaluate the effect of middle-long-term celecoxib administration on the fetus during the second trimester of pregnancy, particularly in terms of fetal DA and amniotic fluid volume.<BR><B>METHODS: </B>We retrospectively extracted and reviewed data from patients with preterm labor who received celecoxib for tocolysis for more than 48 hours between 2016 and 2020. Celecoxib was used for tocolysis only when treatment of patients with conventional tocolytic agents was ineffective. Data on the peak systolic velocity in ductus arteriosus (PSV-DA) and the maximum vertical pocket (MVP) were collected.<BR><B>RESULTS: </B>A total of 15 patients were eligible. The median gestational age at celecoxib introduction was 22.6 weeks, and the median period of administration was 9 days (range 3-40 days). The median gestational age at delivery was 27.1 weeks, and the median duration from initial celecoxib administration to delivery was 40 days. The Z scores of PSV-DA and MVP did not change significantly after celecoxib administration. During administration, PSV-DA exceeded the 95th percentile of the corresponding normal reference range in three cases, but the levels returned to normal after reduction or discontinuation of treatment. There was no oligohydramnios during the treatment.<BR><B>CONCLUSIONS: </B>Celecoxib administration for more than 48 hours in the second trimester of pregnancy might be safe and tolerable in terms of fetal PSV-DA and amniotic fluid volume as long as careful ultrasound monitoring is performed. Celecoxib could be an alternative for preterm labor when conventional tocolysis is not effective.